Q Biomed Inc
We are a biotechnology acceleration and development company focused on acquiring
and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic
products. Currently, we have a portfolio of four therapeutic products, including
an FDA approved product, Strontium 89, a radiopharmaceutical for metastatic
cancer bone pain, and three development stage products: QBM-001 for rare pediatric
non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01
for glaucoma. We aim to maximize risk-adjusted returns by focusing on multiple
assets throughout the discovery and development cycle. We expect to benefit
from early positioning in illiquid and/or less well known privately-held assets,
thereby enabling us to capitalize on valuation growth as these assets move forward
in their development.
Our goal is to become a leading biotechnology acceleration and development
company with a diversified portfolio of therapeutic products commercially available
and in development. To achieve this goal, we are executing on the following
strategy:
Strategically collaborate or in- and out-license select programs.
We seek to collaborate or in- and out-license certain potentially therapeutic
candidate products to biotechnology or pharmaceutical companies for preclinical
and clinical development and commercialization.
Highly leverage external talent and resources.
We plan to maintain and further build our team which is skilled in evaluating
technologies for development and product development towards commercialization.
By partnering with industry specific experts, we are able to identify undervalued
assets that we can fund and assist in enhancing inherent value. We plan to continue
to rely on the extensive experience of our management team to execute on our
objectives.
Evaluate commercialization and monetization strategies on a product-by-product
basis in order to maximize the value of our product candidates or future potential
products.
As we move our drug candidates through development toward regulatory approval,
we will evaluate several options for each drug candidate’s commercialization
or monetization strategy. These options include building our own internal sales
force; entering into a joint marketing partnership with another pharmaceutical
or biotechnology company, whereby we jointly sell and market the product; and
out-licensing any product that we develop by ourselves or jointly with another
party, whereby another pharmaceutical or biotechnology company sells and markets
such product and pays us a royalty on sales. Our decision will be made separately
for each product and will be based on a number of factors including capital
necessary to execute on each option, size of the market to be addressed and
terms of potential offers from other pharmaceutical and biotechnology companies.
It is too early for us to know which of these options we will pursue for our
drug candidates, assuming their successful development.
Acquire commercially or near-commercially ready products and build out the current
market for such.
In addition to acquiring pre-clinical products, in assembling a diversified
portfolio of healthcare assets, we plan on acquiring assets that are either
FDA approved or are reasonably expected to be FDA approved within 12 months
of our acquiring them. We anticipate hiring a contract sales organization to
assume the bulk of the sales and distribution efforts related to any such product.